With hundreds of millions of yuan in funding, BVLASER completes Series C financing round, accelerating global expansion and technological innovation

Recently, Bestview Laser S&T Co., Ltd. (hereinafter referred to as "BVLASER") announced the completion of its Series C financing round, raising over 100 million RMB. This round of financing was led by TigerYeah Capital, with participation from Optics Valley Industrial Investment, Enran Venture Capital, Suzhou Leader Venture Capital, and other institutions. Existing shareholders, including Northern Light Venture Capital and Med-Fine Capital, also continued to invest in this round. Changhai Capital served as the financial advisor for this round.

The successful completion of this round of financing not only demonstrates the capital market's strong recognition of the company's technological capabilities, product competitiveness, and business model, but also inject powerful momentum into its global expansion strategy, brand value enhancement, and core technology iteration, driving greater breakthroughs for domestically produced medical aesthetic laser equipment in the global high-end market.

As a leading enterprise specializing in the R&D, production, and sales of high-end medical aesthetic laser equipment, BVLASER has consistently prioritized technological innovation since its inception, rapidly building a strong technological foundation and a diverse product portfolio. The company focuses on core technologies such as erbium lasers, alexandrite lasers, thulium lasers, and picosecond lasers.  Its independently developed 10+ product lines boast technical indicators that rank among the leading levels domestically. With precise energy control, safe clinical experiences, and stable performance, these products have gained wide favor in the global market.

BVLASER holds over 100 intellectual property rights, and its products are exported to more than 70 countries and regions worldwide, covering diverse application scenarios such as medical aesthetics institutions and dermatology clinics.  The company has achieved consecutive doubled growth in performance over the past three years, establishing itself as a benchmark enterprise for the export of domestic medical aesthetic laser equipment.

The lead investor, TigerYeah Capital, stated: "The medical aesthetics optoelectronics market has long been monopolized by overseas leaders. Domestic equipment suffers from insufficient performance and stability, and mostly competes in the low-end market. Through continuous R&D investment and product innovation, BVLASER has developed a rich product line of more than 10 globally competitive products. The team possesses strong global sales capabilities, and its overseas market is growing rapidly. We look forward to BVLASER continuously innovating and setting a benchmark for domestic products in the field of optoelectronic medical aesthetics."

Existing shareholders Northern Light Venture Capital and Med-Fine Capital have continuously supported BVLASER's development since its early stages and continued to increase their investment in this round, demonstrating their strong confidence in the company's long-term growth: "BVLASER has consistently maintained keen insight and execution in technological innovation and market expansion. We are optimistic about the growth potential of its track and look forward to the company achieving leapfrog development with the help of this round of financing."

It is reported that the funds from this round will focus on three major strategic directions: firstly, in-depth expansion into overseas markets, continuously promoting international registration and compliance certification, and improving the global after-sales service network to benefit more global users with Chinese laser technology. Secondly, a comprehensive upgrade of brand strength, enhancing brand recognition and influence in the international high-end market. And thirdly, continuous iteration of core products, increasing R&D investment, focusing on clinical needs and pain points, and promoting the precise and intelligent upgrading of laser treatment technology to build a more competitive product ecosystem.

The founders and core team of BVLASER stated: "This round of financing is a significant milestone in the company's development. We are grateful for the trust and support of our new and existing shareholders. In the future, BVLASER will continue to uphold its original mission of 'empowering the medical aesthetics industry through technological innovation and serving global users with high-quality products,' accelerating the pace of its global layout. We will efficiently invest the funds in market expansion, brand building, and technological research and development, driving domestic medical aesthetic laser equipment towards higher quality and higher standards, and striving to become a leading brand in the global medical aesthetic laser field."

Following this Series C financing round, BVLASER will further expand its competitive advantage in the global medical aesthetics laser market.  With the planning and construction of its Central China headquarters, the company will build a more comprehensive R&D, production, and operation system. Amidst the continuous expansion of the global medical aesthetics market and the accelerating trend of domestic substitution, BVLASER is expected to achieve leapfrog development through the synergistic efforts of technology, products, and market strategies, contributing more to the implementation of China's "Manufacturing Powerhouse" and "Healthy China" strategies in the medical aesthetics field.